Compare · ABT vs RMTI
ABT vs RMTI
Side-by-side comparison of Abbott Laboratories (ABT) and Rockwell Medical Inc. (RMTI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and RMTI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 7253.8x RMTI ($24.2M).
- Over the past year, ABT is down 19.1% and RMTI is down 45.2% - ABT leads by 26.1 points.
- RMTI has been more active in the news (13 items in the past 4 weeks vs 10 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 3 for RMTI).
- Company
- Abbott Laboratories
- Rockwell Medical Inc.
- Price
- $100.68+1.91%
- $6.17+6.93%
- Market cap
- $175.37B
- $24.2M
- 1M return
- +11.09%
- -9.02%
- 1Y return
- -19.08%
- -45.16%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- News (4w)
- 10
- 13
- Recent ratings
- 25
- 3
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Rockwell Medical Inc.
Rockwell Medical, Inc. operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest RMTI
- Rockwell Medical to Release Second Quarter 2026 Results on Thursday, August 13, 2026
- Director Dawson Joseph H was granted 9,633 shares, increasing direct ownership by 385% to 12,133 units (SEC Form 4)
- Director Nissenson Allen was granted 9,633 shares, increasing direct ownership by 68% to 23,892 units (SEC Form 4)
- Director Lau Joan was granted 9,633 shares, increasing direct ownership by 85% to 20,944 units (SEC Form 4)
- Director Radie Robert S was granted 9,633 shares, increasing direct ownership by 67% to 23,985 units (SEC Form 4)
- Director Cooper John G was granted 9,633 shares, increasing direct ownership by 69% to 23,670 units (SEC Form 4)
- SVP and CCO Chole Timothy was granted 15,000 shares, increasing direct ownership by 122% to 27,285 units (SEC Form 4)
- Chief Operating Officer Hunter Heather was granted 15,000 shares, increasing direct ownership by 115% to 28,007 units (SEC Form 4)
- EVP, CLO & Secretary Timmins Megan C. was granted 15,000 shares, increasing direct ownership by 92% to 31,240 units (SEC Form 4)
- SVP and CFO Neri Jesse was granted 15,000 shares, increasing direct ownership by 123% to 27,239 units (SEC Form 4)